
PRODUCT INFORMATION



Finerenone

Item No. 36086

| | / | / |
|------------------------|--|---|
| CAS Registry No.: | 1050477-31-0 | |
| Formal Name: | (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro- | ~ |
| | 2,8-dimethyl-1,6-naphthyridine-3-carboxamide | |
| Synonym: | BAY 94-8862 | / |
| MF: | $C_{21}H_{22}N_4O_3$ | |
| FW: | 378.4 | |
| Purity: | ≥98% | |
| UV/Vis.: | λ _{max} : 255 nm | |
| Supplied as: | A solid | |
| Storage: | -20°C | |
| Stability: | ≥4 years | |
| Information represente | the product specifications. Batch specific analytical results are provided on each | , |



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Finerenone is supplied as a solid. A stock solution may be made by dissolving the finerenone in the solvent of choice, which should be purged with an inert gas. Finerenone is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of finerenone in these solvents is approximately 3 and 10 mg/ml, respectively.

Description

Finerenone is a non-steroidal mineralocorticoid receptor antagonist ($IC_{50} = 18 \text{ nM}$).¹ It is selective for the mineralocorticoid receptor over glucocorticoid, progesterone, and androgen receptors (IC₅₀s = >10,000 nM for all), as well as L-type calcium channels ($IC_{50} = >10,000$ nM). Finerenone (3 mg/kg) reduces renal vasculopathy, fibrosis, and tubular degeneration, as well as cardiac fibrosis, in a rat model of hypertension-induced end-organ damage.² It also increases exercise capacity and prevents diastolic dysfunction in ovariectomized mice.³

References

- 1. Kolkhof, P., Jaisser, F., Kim, S.-Y., et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at bench and bedside. Handb. Exp. Pharmacol. 243, 271-305 (2017).
- 2. Kolkhof, P., Hartmann, E., Freyberger, A., et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am. J. Nephrol. 52(8), 642-652 (2021).
- 3. Pieronne-Deperrois, M., Guéret, A., Djerada, Z., et al. Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Fail. 8(3), 1933-1943 (2021).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/02/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM